Since DFNA1 patients may have subclinical vulnerability in HCs induced by constitutive activation of DIA1, avoiding NE and pharmacological interventions to reduce disorganized actin polymerization may mitigate progressive hearing loss in DFNA1 patients. Here, DIAPH1 is linked to hearing loss disorder.